New Approval in Early Breast Cancer: First Advance in 20 Years

The CDK4/6 inhibitor abemaciclib (Verzenio) has been approved for use in early breast cancer for certain patients who are at high risk for recurrence.

Related Keywords

Milan ,Lombardia ,Italy ,United Kingdom ,Palo Alto ,California ,United States ,Texas ,Dana Farber Cancer Institute ,Massachusetts ,Brazil ,Stanford University ,Boston ,Houston ,San Antonio ,Oswaldo Cruz ,Rio Grande Do Sul ,London ,City Of ,Stephen Johnston ,Saram Tolaney ,Giuseppe Curigliano ,Pedro Exman ,C Kent Osborne ,Dako Omnis ,Hal Burstein ,European Society Of Medical Oncology ,Twitter ,Drug Administration ,Harvard Medical School ,Division Of Early Drug Development ,Stanford University Medical Center ,European Institute Of Oncology ,European Society ,Medical Oncology ,Royal Marsden Hospital ,Medscape Medical ,Early Drug Development ,European Institute ,Hospital Alem ,Medscape Medical News ,San Antonio Breast Cancer Symposium ,Duncan Cancer Center ,Baylor College ,Clinical Oncology ,Breast Cancer ,Alignant Breast Neoplasm ,Metastatic Breast Carcinoma ,Cancer ,Alignant Neoplasia ,Arcinoma ,Endocrine Therapy ,Hormone Therapy ,Chemotherapy ,Neoplasm ,Tumor ,Fatigue ,Tamoxifen ,Elective Estrogen Receptor Modulator Serm ,Antiretroviral Therapy ,Antiretroviral Therapy Art ,Art ,Atazanavir ,Darunavir ,Travirine ,Ipranavir ,Herapy Antiretroviral ,Hiv Infection ,Shiv ,Nucleoside Rever ,